GPLD1 and neoplasm: The strongest anti-tumor activity was observed with co-treatment of PLD and 100 mg/kg BID peposertib, resulting in long-lasting tumor regression for up to 100 days post treatment start (Figure 5C) It is noteworthy that two tumors in this group relapsed approximately 40 days after cessation of treatment and began to undergo rapid regrowth.